Can a Single Drop of Blood Triage Active Tuberculosis? ESAT-6 Antigen Takes an Early Validation Step Forward

One of the most challenging aspects of tuberculosis is that infected people may not have obvious symptoms, while symptoms such as coughing often resemble those of other lung diseases. Current diagnosis relies largely on sputum samples, but patients may be unable to produce sputum successfully, and cultures also require time. Researchers therefore turned to blood, attempting to directly capture the ESAT-6 antigen produced by Mycobacterium tuberculosis in search of a faster triage signal for active pulmonary tuberculosis.

In a study presented at the 2026 Association for Diagnostics & Laboratory Medicine annual meeting, the team analyzed blood from 217 participants, including people with active pulmonary tuberculosis, latent tuberculosis infection, people who had been exposed but were not infected, and controls with diseases such as nontuberculous mycobacterial lung disease and lung cancer. The results showed that circulating ESAT-6 concentrations increased in a stepwise pattern from exposed but uninfected participants to those with latent infection and then to those with active tuberculosis.

This association remained after adjustment for age, sex, and diabetes. The study report also stated that ESAT-6 outperformed two commonly used blood markers in distinguishing among different clinical tuberculosis groups. This matters because latent infection means that tuberculosis bacteria are already present in the body, but it does not mean that disease is active or that the transmission risk is the same. The ability to identify active disease is the central issue in clinical triage and public health intervention.

ESAT-6 is not an indirect product of the human inflammatory response but a protein secreted by tuberculosis bacteria, making it theoretically more closely tied to the pathogen itself. An electrochemical biosensor published earlier within the same line of research used a polymer-modified gold electrode to detect ESAT-6 in blood. It reported a detection limit of 1.39 picomolar and could produce results within 4 minutes; at that time, its sensitivity for distinguishing patients with pulmonary tuberculosis from healthy participants was 95%, with specificity of 100%.

However, these striking figures cannot be regarded directly as the new study's performance in real-world healthcare settings. The earlier trial primarily used healthy people as controls, which is generally an easier comparison than distinguishing tuberculosis from lung cancer, nontuberculous mycobacterial infection, or other diseases with similar symptoms. The newly presented analysis of 217 people used retrospective clinical classification and may likewise have been affected by enrollment methods, disease severity, and population composition. The study also observed higher ESAT-6 levels in smear-positive patients, suggesting that the signal may vary with bacterial burden, but this also means that people with a lower bacterial burden may be more difficult to detect.

Accordingly, the more reasonable near-term role for this blood marker is not stand-alone diagnosis, but helping determine who should be prioritized for further testing when sputum is difficult to obtain or testing is delayed. Sputum culture and molecular testing remain responsible for confirming infection and providing the drug-resistance information essential to treatment. The research team is planning prospective validation that more closely reflects actual clinical workflows. Only if the ESAT-6 blood test maintains its accuracy among consecutively enrolled patients with more complex disease backgrounds could it truly shorten the time from suspicion of active tuberculosis to management.